Literature DB >> 9517497

Human herpesvirus 8 (HHV-8) in the pathogenesis of Kaposi's sarcoma and other diseases.

R W Humphrey1, D A Davis, F M Newcomb, R Yarchoan.   

Abstract

The discovery of Kaposi's Sarcoma-associated herpesvirus/human herpesvirus-8 (KSHV/ HHV-8) and subsequent studies of this virus have provided a body of evidence that support the concept that this is an etiologic agent for Kaposi's sarcoma (KS). Several studies have indicated that this virus may also be a causal agent for primary effusion lymphoma (PEL) and Castleman's disease as well. First generation serologic assays for HHV-8 have now been developed. The preponderance of data suggest that the incidence of HHV-8 infection is highest in populations at risk for KS: male homosexuals, immunosuppressed patients, and those who live in endemic regions. HHV-8 encodes for functional homologs of human proteins that may play a role in the development of disease. As we learn more about the steps by which this virus can lead to KS and/or other diseases, rational therapies and preventative strategies may be possible.

Entities:  

Mesh:

Year:  1998        PMID: 9517497     DOI: 10.3109/10428199809092681

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  3 in total

1.  Anti-CD20 monoclonal antibody treatment of human herpesvirus 8-associated, body cavity-based lymphoma with an unusual phenotype in a human immunodeficiency virus-negative patient.

Authors:  C L Pérez; S Rudoy
Journal:  Clin Diagn Lab Immunol       Date:  2001-09

2.  Latent KSHV infection increases the vascular permeability of human endothelial cells.

Authors:  Christophe Guilluy; Zhigang Zhang; Prasanna M Bhende; Lisa Sharek; Ling Wang; Keith Burridge; Blossom Damania
Journal:  Blood       Date:  2011-08-31       Impact factor: 22.113

3.  Survival and clonal expansion of mutating "forbidden" (immunoglobulin receptor-deficient) epstein-barr virus-infected b cells in angioimmunoblastic t cell lymphoma.

Authors:  A Bräuninger; T Spieker; K Willenbrock; P Gaulard; H H Wacker; K Rajewsky; M L Hansmann; R Küppers
Journal:  J Exp Med       Date:  2001-10-01       Impact factor: 14.307

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.